Navigation Links
Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2013 Sales And EPS Of $675 Million And $1.01, Respectively, Both Record Quarterly Highs. Reaffirms Full Year 2013 Diluted Adjusted EPS Outlook Of $4.10 To $4.20.
Date:4/25/2013

growth of our Life Science Products and Services.  We remain well positioned to benefit from the therapeutic trend to biologics and high-potency compounds, which was again evidenced by solid growth in our industrial cell culture media business and strong double-digit growth in our custom pharma business.  BioReliance achieved a solid quarter with mid-single digit organic sales growth.  As expected, year-over-year price declines for chemical precursors to the LED industry resulted in lower sales in our Hitech electronics segment.  We are launching new products for the semiconductor and electronic display markets, which are not as price sensitive as the LED market, and are expected to provide growth in the second half of the year.

We generated strong free cash flow in the quarter and raised our cash dividend for the 38th consecutive year.  We continue to look for growth investments, both organic and inorganic, that fit our strategy of increasing our presence in faster growing Applied and Commercial markets, broadening our Research portfolio to leverage our worldwide sales and distribution channels, increasing our presence in faster growing emerging countries and generating opportunities to significantly increase shareholder value."

Q1 2013 RESULTS:Reported sales for the first quarter of 2013 were $675 million, a 2% increase from the first quarter of 2012.  Organic sales growth in the quarter was 1%.  Acquisitions completed in 2012 increased sales by 2% and changes in foreign currency exchange rates caused sales to decline by 1%. 

Research ($361 million in sales, 53% of overall sales)

  • Organic sales declined by 1%.  Changes in foreign currency exchange rates reduced overall Research growth by 2%.
  • Excluding the impact from fewer shipping days, Research sales would have grown organically in the low-single digits.
  • Academic/Government organic sales growth declined in
    '/>"/>

  • SOURCE Sigma-Aldrich
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related medicine technology :

    1. Sigma-Aldrich Announces Q1 2013 Earnings Conference Call
    2. Sigma-Aldrich Corporations Sigma Life Science Business to Distribute Worldwide Olink Biosciences Protein Interaction Analysis Technology
    3. Sigma-Aldrich Reports Record Full Year 2012 Results. Reports Q4 2012 Diluted EPS Of $0.96. Q4 2012 Sales Increased 7%. Full Year 2012 Adjusted Diluted EPS Was $3.85. Expects Full Year 2013 Adjusted Diluted EPS To Increase To $4.10 - $4.20.
    4. Sigma-Aldrich Aligns Into Three New Market-Focused Business Units
    5. Sigma-Aldrich (NASDAQ: SIAL) Declares $0.20 Quarterly Dividend
    6. Sigma-Aldrich Enhances Customer Focus in China - Unveils Dynamic New Website and Expands Product Offering Through Vetec Brand
    7. Sigma-Aldrich Corporation To Present At Upcoming Investor Conferences
    8. Sigma-Aldrich Accelerates Analytical Research and Extends Benefits of Fused-Core Particle Technology to All HPLC Users with the Launch of New Ascentis Express 5 Micron Particle by Supelco
    9. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
    10. Morgan & Morgan Announces Investigation of MAP Pharmaceuticals (NASDAQ: MAPP)
    11. SHAREHOLDER ALERT: Morgan & Morgan announces an investigation of Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) and whether senior management and the board of directors violated fiduciary duties owed to Vertex shareholders.
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/22/2014)... ., Aug. 22, 2014  Research presented at the ... therapy being developed by Hera Therapeutics Inc. combats three types ... of all cervical cancer. When tested in several ... HPV-18 and HPV-11 cells, according to Louise T. Chow ... the findings at the Seattle conference. ...
    (Date:8/22/2014)... /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD), a ... technologies and products for advanced microarray diagnostics, today ... Service Agreement to contract with a UK-based company ... the initial phase of this agreement, SQI will ... of one of the customer,s assays, operational on ...
    (Date:8/21/2014)... Ill. , Aug. 21, 2014 ... Baxter International Inc. today announced positive results from ... 855, an investigational, extended half-life recombinant factor VIII ... [Antihemophilic Factor (Recombinant)], which met its primary endpoint ... prophylaxis arm compared to the on-demand arm. ...
    Breaking Medicine Technology:Study shows Hera Therapeutics experimental compound shuts down human papillomavirus that causes most cervical cancer 2SQI Diagnostics Contracted to Automate Pathogen Detection Assays 2SQI Diagnostics Contracted to Automate Pathogen Detection Assays 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5
    ... in combination with the most commonly used doses of ... patients with mixed dyslipidemiaORLANDO, Fla., March 29 Data ... TRILIPIX(R) (fenofibric acid) delayed-release capsules in combination with rosuvastatin ... TRILIPIX 135 mg in combination with rosuvastatin calcium 5 ...
    ... March 29 A new analysis from the,JUPITER ... the risk of venous thromboembolism (VTE) by 43% ... with low to normal cholesterol levels and elevated,high-sensitivity ... the 58th Annual American College of Cardiology Scientific ...
    Cached Medicine Technology:New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 2New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 3New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 4New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 5CRESTOR(R) Reduced Risk of Blood Clots in the Veins 2CRESTOR(R) Reduced Risk of Blood Clots in the Veins 3CRESTOR(R) Reduced Risk of Blood Clots in the Veins 4
    (Date:8/22/2014)... NV (PRWEB) August 22, 2014 Mi40x ... uses university-proven research to show people how they can use ... muscle in only a matter of weeks has caught the ... “Ben Pakulski is one of the most well-known bodybuilders in ... the body he has today, that in itself is a ...
    (Date:8/22/2014)... Paying tuition and other related educational ... year for four nurse educators pursuing advanced degrees, thanks ... Nursing Foundation for Nursing Education . This year’s recipients ... more than in 2013, thanks to these named NLN ... Isaac Marcil Endowment Funds, both donated by Kathy Mershon; ...
    (Date:8/22/2014)... Wisconsin (PRWEB) August 22, 2014 Mueller ... for Plantar Fasciitis, an exciting new product that provides ... you to stay active while you heal. The package ... is truly a new technology – it is not ... , FasciaDerm® PFTape™ System for Plantar Fasciitis ...
    (Date:8/22/2014)... A new study of self-awareness by Kessler Foundation ... may be able to improve their self-awareness through ... of print on July 2 in NeuroRehabilitation ... D. Chiaravalloti & John DeLuca: Metacognitive knowledge and ... 10.3233/NRE-141113). Self-awareness is one,s ability to recognize cognitive ...
    (Date:8/22/2014)... 2014 Menstrual leaks risk stains and ... Fla., decided that there needed to be a better ... and producible in design variations, the Safety Net optimizes ... which avoids embarrassment and promotes peace of mind. The ... , The original design was submitted to the Fort ...
    Breaking Medicine News(10 mins):Health News:Mi40x: Review Exposes Ben Pakulski’s Guide to Packing on Lean Muscle Fast 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 3Health News:Mueller Introduces FasciaDerm® PFTape™ System for Plantar Fasciitis 2Health News:Kessler Foundation study of self-awareness in MS has implications for rehabilitation 2
    ... gene (MTDH) plays a role in both cancer metastasis ... Press in the January 6th issue of the journal ... therapeutic target for high risk breast cancers. , "Most ... succumb to recurrent tumors that spread to distant vital ...
    ... , The Fifth International Conference on Cell Therapy ... on stem cells for non-cardiac organ injury. The session ... disease and diabetes, bone marrow cells for stroke patients, ... , Highlights from other sessions include the first human ...
    ... in the U.S. each year have been exposed to alcohol or ... by the National Center on Substance Abuse and Child Welfare. If ... remain in foster care longer, and chances are very low that ... study led by Joseph P. Ryan, a faculty member in the ...
    ... PR Newswire Staff Volunteer Time As Part ... InitiativeCLEVELAND, Jan. 5 Ronald McDonald House of ... two non-profit organizations serving the Cleveland community, were ... hours from PR Newswire,s Cleveland staff in 2008, ...
    ... cost Medicaid hundreds of millions of dollars annually in ... could not only improve outcomes but also save substantial ... examined records of nearly 150,000 people in six states. ... more than they think," said Robin E. Clark, PhD, ...
    ... OF PLASTIC SURGEONSARLINGTON HEIGHTS, Ill., Jan. 5 The ... Plastic Surgeons:Can The US Really Cut Health Care Spending? ... is one of the strongest sectors of the ailing ... health care spending is not probable. The author, who ...
    Cached Medicine News:Health News:Gene plays dual role in breast cancers with poor prognosis 2Health News:Conference on cell therapy includes new session on stem cells for non-cardiac organ injury 2Health News:'Recovery coaches' effective in reducing number of babies exposed to drugs 2Health News:'Recovery coaches' effective in reducing number of babies exposed to drugs 3Health News:PR Newswire Provides Grant to Ronald McDonald House and Habitat for Humanity in Cleveland 2Health News:PR Newswire Provides Grant to Ronald McDonald House and Habitat for Humanity in Cleveland 3Health News:PR Newswire Provides Grant to Ronald McDonald House and Habitat for Humanity in Cleveland 4Health News:PR Newswire Provides Grant to Ronald McDonald House and Habitat for Humanity in Cleveland 5Health News:Substance abuse adds millions to Medicaid's total health care costs 2Health News:Substance abuse adds millions to Medicaid's total health care costs 3Health News:Plastic and Reconstructive Surgery...In Brief 2Health News:Plastic and Reconstructive Surgery...In Brief 3
    Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
    Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
    Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
    Kleinert-Kutz Single Skin Hook, Large...
    Medicine Products: